FAS and neoplasm: The following biological assays evaluated the MA cytotoxic activity against selected preclinical human tumor models overexpressing FAS (i.e., the MCF-7 estrogen-responsive breast adenocarcinoma and the MDA-MB-231 triple-negative breast adenocarcinoma) and confirmed the MA inhibitory action on the FAS enzymatic activity.